Dr. Vivek's AI Dr. Vivek's AI
Support us
🔗 You are viewing a shared knowledge page for: Diabetic Ketoacidosis
← New Search

Diabetic Ketoacidosis

Educational clinical summary of Diabetic Ketoacidosis for doctors and students: definition, workup, management, and key caveats. Not a substitute for guidelines.

Maintained by Dr. Vivek Karn Review process: editorial policy

Disclaimer: This document provides comprehensive medical information for educational purposes and as a clinical reference. It is not a substitute for professional medical advice, diagnosis, or treatment. Clinical decisions must always be made by a qualified healthcare professional based on individual patient circumstances and sound clinical judgment. Treatment protocols may vary based on institutional guidelines and specific patient needs.

Overview

  • Definition: Diabetic ketoacidosis (DKA) is an acute, life-threatening complication of diabetes mellitus characterized by a triad of hyperglycemia, high anion gap metabolic acidosis, and ketonemia. It results from a severe absolute or relative insulin deficiency combined with an increase in counter-regulatory hormones (glucagon, catecholamines, cortisol, growth hormone).
  • Epidemiology:
    • Accounts for approximately 1-2% of all hospital admissions in patients with diabetes.
    • More common in type 1 diabetes mellitus (T1DM), often being the initial presentation (25-40% of cases).
    • Increasingly seen in type 2 diabetes mellitus (T2DM) patients, especially those with severe illness, infection, or using certain medications like SGLT2 inhibitors.
    • Incidence rates vary from 4-8 episodes per 1000 diabetic patients per year.
    • Mortality rates have significantly declined but remain around 0.2-2%, higher in elderly patients, those with severe DKA, or with significant comorbidities.

  • Classification: DKA severity is classified based on biochemical criteria as per the American Diabetes Association (ADA):

    Parameter Mild DKA Moderate DKA Severe DKA
    Plasma Glucose (mg/dL) >250 >250 >250
    Arterial pH 7.25 – 7.30 7.00 – <7.25 <7.00
    Bicarbonate (mEq/L) 15 – <18 10 – <15 <10
    Urine Ketones Positive Positive Positive
    Serum Ketones Positive (β-hydroxybutyrate >3.0 mmol/L) Positive (β-hydroxybutyrate >3.0 mmol/L) Positive (β-hydroxybutyrate >3.0 mmol/L)
    Effective Serum Osmolality (mOsm/kg) Variable Variable Variable
    Anion Gap (mEq/L) >10 >12 >12
    Mental Status Alert Alert/Drowsy Stupor/Coma

    Note: Anion Gap = Na+ - (Cl- + HCO3-)

Pathophysiology

  • Mechanism: DKA is triggered by a critical shortage of insulin, leading to several metabolic derangements:
    1. Hyperglycemia: Lack of insulin leads to decreased glucose utilization by peripheral tissues and unrestrained hepatic glucose production (gluconeogenesis and glycogenolysis) due to unopposed action of counter-regulatory hormones (glucagon, cortisol, catecholamines, growth hormone). This results in severe hyperglycemia (>250 mg/dL).
    2. Osmotic Diuresis and Dehydration: High blood glucose levels exceed the renal threshold, leading to glucosuria. This causes an osmotic diuresis, resulting in significant fluid and electrolyte losses (water, sodium, potassium, phosphate, magnesium), leading to dehydration and effective hypovolemia.
    3. Ketoacidosis: Insulin deficiency shifts metabolism from glucose utilization to fat breakdown (lipolysis). This releases free fatty acids (FFAs) which are then transported to the liver and converted into ketone bodies (acetoacetate, β-hydroxybutyrate, and acetone) via β-oxidation. The accumulation of these acidic ketone bodies (especially β-hydroxybutyrate) overwhelms the body's buffer systems, leading to a high anion gap metabolic acidosis.
    4. Electrolyte Derangements: Initial hyperkalemia may be present due to insulin deficiency-induced shift of potassium out of cells and acidosis. However, total body potassium is significantly depleted due to osmotic diuresis and vomiting. Phosphate and magnesium depletion also occurs.
  • Risk Factors:
    • Infection: The most common precipitating factor (e.g., pneumonia, urinary tract infection, sepsis, gastroenteritis).
    • Insulin Non-Adherence: Intentional (e.g., omission due to psychological issues, cost) or unintentional (e.g., poor understanding, technical issues with insulin pump).
    • New Diagnosis of Type 1 Diabetes: DKA is the initial presentation in a significant proportion of children and adolescents with T1DM.
    • Myocardial Infarction (MI), Stroke, Pancreatitis: Acute stress conditions increase counter-regulatory hormones.
    • Certain Medications: Glucocorticoids, thiazide diuretics, sympathomimetics, antipsychotics, and SGLT2 inhibitors (can cause euglycemic DKA).
    • Trauma or Surgery: Physiologic stress.
    • Eating Disorders: Especially in young women with T1DM (insulin omission for weight loss, "diabulimia").
    • Psychological Stress: Emotional distress can trigger DKA.
    • Pump Failure/Malfunction: In insulin pump users.
  • Protective Factors:
    • Effective Diabetes Education: Understanding sick day rules, insulin management, and ketone monitoring.
    • Consistent Insulin Adherence: Regular and appropriate use of insulin therapy.
    • Prompt Medical Attention: Seeking care early during illness or when symptoms of hyperglycemia/ketosis appear.
    • Frequent Blood Glucose Monitoring: Timely detection of elevated glucose levels.
    • Availability of Support Systems: Access to healthcare professionals and social support.

Clinical Presentation

Signs and Symptoms

  • Cardinal Features:
    • Polyuria and Polydipsia: Due to osmotic diuresis and subsequent dehydration.
    • Weight Loss: From fluid depletion and catabolism.
    • Fatigue and Weakness: General malaise, electrolyte imbalances.
    • Nausea, Vomiting, Abdominal Pain: Common due to acidosis, electrolyte shifts, and ileus. Can mimic acute abdomen.
    • Kussmaul Respirations: Deep, rapid breathing, an attempt to compensate for metabolic acidosis by blowing off CO2.
    • Fruity Odor to Breath: Distinctive acetone smell.
    • Altered Mental Status: From lethargy to stupor or coma, often correlating with the severity of acidosis and hyperosmolality.
  • Early Signs:
    • Increased thirst and urination.
    • Generalized weakness and fatigue.
    • Nausea and decreased appetite.
  • Advanced Signs:
    • Severe dehydration (dry mucous membranes, sunken eyes, decreased skin turgor).
    • Hypotension and tachycardia (signs of hypovolemic shock).
    • Rapid, deep (Kussmaul) respirations.
    • Profound abdominal pain, vomiting, and decreased bowel sounds.
    • Significant altered mental status (drowsiness, stupor, coma).
  • Atypical Presentations:
    • Euglycemic DKA: Occurs with blood glucose levels <250 mg/dL, most commonly seen with SGLT2 inhibitor use, but also in pregnancy, prolonged fasting, or liver disease. The key is the acidosis and ketonemia.
    • DKA with Minimal Abdominal Pain: Abdominal pain is common, but its absence does not rule out DKA.
    • Normal pH DKA: Very rare, may occur if there is coexisting alkalosis (e.g., prolonged vomiting leading to metabolic alkalosis while DKA causes metabolic acidosis).
    • DKA in type 2 diabetes: Less common, often associated with severe stress, infection, or specific medications.

Physical Examination

  • Inspection:
    • General Appearance: Appears ill, lethargic, or agitated.
    • Hydration Status: Dry mucous membranes, sunken eyeballs, decreased skin turgor (especially in children/elderly).
    • Respiratory Pattern: Kussmaul respirations (deep and rapid).
    • Fruity Breath Odor: Acetone smell.
    • Signs of Infection: Fever, localized erythema, purulence (e.g., pneumonia, UTI, cellulitis).
  • Palpation:
    • Peripheral Pulses: Rapid and thready.
    • Capillary Refill: Prolonged (>2 seconds).
    • Abdomen: May be tender, especially in the epigastric region; rebound tenderness is rare unless there's true surgical abdomen. Bowel sounds may be diminished or absent.
  • Special Tests:
    • Orthostatic Hypotension: Significant drop in blood pressure upon standing, indicating significant dehydration.
    • Neurological Examination: Assess mental status (Glasgow Coma Scale), pupillary response, and focal neurological deficits (rare, but consider cerebral edema).

Diagnostic Approach

History Taking

  • Key Questions:
    • Diabetes History: Type of diabetes, duration, current insulin regimen (type, dose, frequency), other anti-diabetic medications (e.g., SGLT2 inhibitors).
    • Recent Illness/Stressors: Any recent infections (flu-like symptoms, fever, cough, dysuria), trauma, surgery, MI, stroke?
    • Insulin Adherence: Any missed insulin doses, problems with insulin delivery device (pump failure), or intentional omission?
    • Symptoms of DKA: Onset and duration of polyuria, polydipsia, weight loss, nausea, vomiting, abdominal pain, altered mental status, Kussmaul breathing.
    • Sick Day Management: What did the patient do during illness (e.g., increased fluid intake, checked ketones)?
    • Comorbidities: Heart disease, kidney disease, hypertension.
    • Medication History: Including new medications, corticosteroids, antipsychotics.
  • Red Flags:
    • Rapid onset of symptoms in a known diabetic.
    • Persistent vomiting and inability to keep fluids down.
    • Severe abdominal pain.
    • Rapid breathing (Kussmaul) and fruity breath.
    • Any alteration in mental status (lethargy, confusion, stupor, coma).
    • Signs of shock (hypotension, tachycardia).

Laboratory Tests

  • First-Line:
    • Blood Glucose: Typically >250 mg/dL (can be lower in euglycemic DKA).
    • Electrolytes: Sodium (may be pseudohyponatremia due to hyperglycemia; corrected Na = Measured Na + 0.016 * (glucose - 100)), potassium (initial levels can be normal, low or high, but total body potassium is depleted), chloride.
    • Bicarbonate (HCO3-): Decreased (<18 mEq/L) due to metabolic acidosis.
    • Blood Urea Nitrogen (BUN) and Creatinine (Cr): Elevated due to dehydration and prerenal acute kidney injury.
    • Arterial Blood Gas (ABG) or Venous Blood Gas (VBG):
      • pH: Decreased (<7.3). VBG pH is usually 0.02-0.03 units lower than ABG.
      • pCO2: Decreased (compensatory hyperventilation).
      • pO2: Usually normal.
    • Anion Gap: Elevated (>10-12 mEq/L). Calculated as Na+ - (Cl- + HCO3-).
    • Urine Ketones: Positive (Acetoacetate). While qualitative, useful for initial screen.
    • Serum Ketones (Beta-hydroxybutyrate): Quantitative measurement, preferred for diagnosis and monitoring resolution as β-hydroxybutyrate is the predominant ketone body in DKA and acetoacetate (detected by urine dipsticks) decreases as DKA resolves (converting back to β-hydroxybutyrate). Levels typically >3.0 mmol/L.
    • Complete Blood Count (CBC): Leukocytosis (often without infection) due to stress. Hemoconcentration (elevated Hct).
    • Urinalysis: Glucosuria, ketonuria. Look for signs of UTI (nitrites, leukocyte esterase, bacteria).
    • Cardiac Enzymes: If MI is suspected as precipitating factor.
  • Confirmatory:
    • Simultaneous presence of:
      • Blood glucose >250 mg/dL (or <250 mg/dL in euglycemic DKA).
      • Arterial pH <7.3 (or VBG pH <7.27).
      • Bicarbonate <18 mEq/L.
      • Elevated anion gap (>10-12 mEq/L).
      • Presence of serum ketones (β-hydroxybutyrate >3.0 mmol/L or positive urine ketones).
  • Monitoring:
    • Blood Glucose: Hourly or every 2 hours initially.
    • Electrolytes (K+, Na+, Cl-, HCO3-): Every 2-4 hours, especially potassium.
    • Anion Gap: Every 2-4 hours, until it normalizes.
    • Serum Beta-hydroxybutyrate: Every 2-4 hours to monitor resolution of ketosis.
    • Venous Blood Gas (VBG): Every 2-4 hours to monitor pH and bicarbonate.

Imaging

  • Recommended:
    • Chest X-ray: If respiratory symptoms, fever, or suspicion of pneumonia.
    • Urinalysis with culture: If suspicion of urinary tract infection.
    • ECG: To assess for cardiac abnormalities, especially if chest pain, or for effects of hyperkalemia/hypokalemia.
  • Advanced:
    • Abdominal Imaging (CT or Ultrasound): If severe, persistent, or atypical abdominal pain to rule out intra-abdominal pathology (e.g., appendicitis, pancreatitis, cholecystitis) or if DKA fails to resolve after initial therapy.
    • Head CT or MRI: If neurological decline (worsening mental status, focal neurological signs, new seizures) despite improving metabolic parameters, to rule out cerebral edema (rare but devastating complication, especially in children) or stroke.

Management

DKA management requires aggressive fluid replacement, insulin therapy, electrolyte correction, and identification/treatment of the precipitating cause. Close monitoring is essential.

Acute Management

  • Immediate (First 1-2 Hours):
    1. Airway, Breathing, Circulation (ABCs): Assess and stabilize. Provide oxygen if SpO2 <92%.
    2. IV Access: Establish two large-bore intravenous lines.
    3. Fluid Resuscitation: This is the most critical initial step.
      • Adults:
        • Start with 0.9% Normal Saline (NS): 1-1.5 L during the first hour.
        • Then, administer 15-20 mL/kg/hr for the next 1-2 hours (typically 500-1000 mL/hr).
        • Adjust fluid rate based on hydration status, hemodynamics, and cardiac status.
        • If corrected serum sodium is normal or high, consider switching to 0.45% NS (half-normal saline) at 250-500 mL/hr to avoid hypernatremia and rapid sodium increase.
        • When blood glucose reaches 200 mg/dL, change IV fluids to D5NS (5% Dextrose in 0.9% NS) or D5W with 0.45% NS at 150-250 mL/hr to prevent hypoglycemia and allow continued insulin administration until DKA resolves.
      • Pediatrics: More cautious fluid administration (10-20 mL/kg NS bolus over 30-60 min), followed by maintenance fluids + deficit replacement over 24-48 hours. Avoid rapid fluid shifts to minimize cerebral edema risk.
    4. Insulin Therapy (after initial fluid bolus):
      • Adults:
        • Administer a regular insulin bolus 0.1 units/kg IV (optional, some guidelines omit).
        • Initiate continuous regular insulin infusion at 0.1 units/kg/hr IV.
        • The goal is to decrease blood glucose by 50-75 mg/dL/hr. If glucose reduction is not achieved, increase insulin infusion rate by 0.05-0.1 units/kg/hr every hour.
      • Pediatrics: Regular insulin infusion at 0.05-0.1 units/kg/hr IV (no initial bolus recommended due to cerebral edema risk).
    5. Potassium Replacement: DKA patients are total body potassium depleted despite normal or elevated initial serum potassium.
      • If serum K+ is <3.3 mEq/L: HOLD insulin infusion; administer 20-40 mEq/hr K+ IV until K+ is >3.3 mEq/L. Resume insulin once K+ is safe.
      • If serum K+ is 3.3-5.2 mEq/L: Add 20-30 mEq K+ to each liter of IV fluid. Goal is to keep K+ between 4-5 mEq/L.
      • If serum K+ is >5.2 mEq/L: Do NOT add K+ to IV fluids, but recheck K+ every 2 hours; once K+ drops, start replacement.
    6. Identify and Treat Precipitating Cause: Perform targeted history, physical exam, and initial labs to identify infection, MI, stroke, etc., and initiate appropriate therapy (e.g., antibiotics).
  • Stabilization (Ongoing Management):
    1. Continuous Monitoring: Hourly glucose, every 2-4 hour electrolytes (Na, K, Cl, HCO3), anion gap, serum beta-hydroxybutyrate, VBG (pH). Continuous cardiac monitoring for dysrhythmias due to potassium shifts. Vital signs, fluid input/output.
    2. Fluid Adjustment: Continue adjusting IV fluid type and rate based on hydration status, blood pressure, and corrected sodium.
    3. Insulin Infusion Titration: Adjust insulin rate to achieve a target blood glucose reduction of 50-75 mg/dL/hr. Continue insulin infusion until resolution of DKA (anion gap closure, HCO3 >18 mEq/L, and β-hydroxybutyrate <0.6 mmol/L or negative ketones on urine dipstick).
    4. Bicarbonate Therapy: Generally NOT recommended in DKA unless pH <6.9, due to risks of cerebral edema, paradoxical CSF acidosis, hypokalemia, and delayed lactate clearance.
      • If pH <6.9, consider 100 mmol sodium bicarbonate in 400 mL sterile water with 20 mEq KCl given over 2 hours. Recheck pH every 2 hours.
    5. Phosphate Replacement: Not routinely recommended. Consider if serum phosphate <1.0 mg/dL, cardiac dysfunction, respiratory depression, or hemolytic anemia. Administer 20-30 mEq potassium phosphate over several hours.
  • Emergency (Specific Crisis Management):
    • Hypovolemic Shock: Aggressive fluid boluses of NS (e.g., 500-1000 mL rapidly). Consider vasopressors if fluids alone are insufficient.
    • Severe Hyperkalemia (K >6.5 mEq/L with ECG changes): Insulin and glucose (e.g., 10 units regular insulin + 50 mL D50W), calcium gluconate (10 mL 10% IV over 5-10 min) to stabilize myocardium, inhaled beta-agonists, furosemide, consider dialysis if refractory.
    • Cerebral Edema: Immediate treatment with mannitol (0.25-1 g/kg IV over 20-30 min) or hypertonic saline (2.5-5 mL/kg 3% NaCl over 30 min), elevate head of bed, hyperventilation, emergent neuroimaging. Often requires ICU admission.

Chronic Management

  • Pharmacological:
    • Transition from IV to Subcutaneous Insulin: Once DKA has resolved (glucose <200 mg/dL, pH >7.3, HCO3 >18 mEq/L, anion gap <12 mEq/L, and patient can tolerate oral intake), initiate subcutaneous (SQ) insulin.
      • Give first dose of long-acting insulin (e.g., basal insulin such as glargine or detemir) 1-2 hours BEFORE discontinuing IV insulin infusion.
      • For patients already on insulin, resume their home regimen or adjust as needed.
      • For new-onset T1DM, start a basal-bolus regimen (e.g., 0.5-0.7 units/kg/day total daily dose, divided into basal and prandial insulin).
    • Manage Precipitating Factor: Continue antibiotics for infections, manage cardiovascular events, etc.
  • Non-pharmacological:
    • Patient Education: Crucial to prevent recurrence.
      • Sick Day Rules: How to manage insulin and glucose when ill (increase fluid intake, frequent glucose and ketone monitoring, never omit insulin, know when to seek medical help).
      • Insulin Management: Proper storage, injection technique, adjustment for diet/exercise.
      • Nutritional Counseling: Balanced diet, carbohydrate counting.
      • Regular Follow-up: With endocrinologist and diabetes educator.
    • Psychological Support: For patients with recurrent DKA due to insulin omission related to psychological issues or eating disorders.
  • Monitoring:
    • HbA1c: To assess long-term glycemic control.
    • Self-Monitoring of Blood Glucose (SMBG): Regular checks, especially during illness.
    • Ketone Monitoring: Urine or blood ketone testing advised during illness, stress, or hyperglycemia.
    • Routine Diabetes Complication Screening: Annual eye exams, foot exams, kidney function monitoring (urine albumin/creatinine ratio, GFR).
    • Blood Pressure and Lipid Management: As part of comprehensive diabetes care.

Treatment Algorithms

  • First-Line (General DKA Protocol):
    1. Fluids: 1-1.5 L NS IV bolus over first hour. Then 0.9% NS at 250-500 mL/hr, switching to 0.45% NS if corrected Na+ is normal/high. When glucose <200 mg/dL, switch to D5NS or D5W with 0.45% NS.
    2. Insulin: 0.1 units/kg regular insulin IV bolus (optional), then 0.1 units/kg/hr continuous IV infusion.
    3. Potassium:
      • K+ <3.3 mEq/L: Stop insulin, give 20-40 mEq/hr K+.
      • K+ 3.3-5.2 mEq/L: Add 20-30 mEq K+ to each liter of IV fluid.
      • K+ >5.2 mEq/L: Do not give K+, recheck q2h.
    4. Bicarbonate: Only if pH <6.9 (100 mmol NaHCO3 in 400 mL H2O with 20 mEq KCl over 2 hours).
    5. Identify and Treat Precipitating Cause.
    6. Monitor: Glucose, electrolytes, anion gap, beta-hydroxybutyrate, VBG q2-4h.
  • Second-Line (Adjustments based on response):
    • If glucose not dropping by 50-75 mg/dL/hr: Increase insulin infusion rate.
    • If glucose drops too quickly: Increase dextrose concentration in fluids.
    • If K+ still low despite replacement: Increase K+ administration rate.
    • If anion gap not closing: Continue insulin, ensure adequate fluids and K+.
  • Refractory Cases:
    • Persistent Acidosis/Ketosis:
      • Ensure insulin infusion is running correctly and patient is responsive to insulin (e.g., check for insulin resistance).
      • Reassess for missed underlying causes (e.g., undiagnosed infection, non-compliance with insulin, drug-induced DKA, pancreatic issues).
      • Consider increasing insulin infusion rate further (e.g., 0.15-0.2 units/kg/hr) if appropriate.
      • Verify proper fluid administration and electrolyte balance.
    • Recurrent DKA: Requires intensive patient education, psychological evaluation, and possibly behavioral therapy to address insulin omission or other contributing factors. Consider insulin pump therapy in selected cases.

Complications

  • Common:
    • Hypoglycemia: Due to over-aggressive insulin therapy or delay in changing fluids to dextrose-containing solutions.
    • Hypokalemia: Due to insulin-mediated potassium shift into cells and continued renal losses; can lead to cardiac arrhythmias.
    • Fluid Overload/Pulmonary Edema: Especially in patients with underlying cardiac or renal insufficiency, or due to overly aggressive fluid resuscitation.
    • Acute Kidney Injury (AKI): Usually pre-renal due to dehydration, reversible with fluid resuscitation.
  • Serious:
    • Cerebral Edema: Rare but devastating, most common in children, new-onset T1DM, and with rapid correction of glucose or osmolality. Presents with headache, vomiting, lethargy, pupillary changes, bradycardia, hypertension, and ultimately coma.
    • Acute Respiratory Distress Syndrome (ARDS): Non-cardiogenic pulmonary edema.
    • Vascular Thrombosis (DVT, PE, Stroke): DKA creates a hypercoagulable state due to dehydration, increased blood viscosity, and endothelial dysfunction.
    • Rhabdomyolysis: Rare, but can occur with severe dehydration and electrolyte imbalances.
    • Mucormycosis: A rare but aggressive fungal infection seen in severe DKA patients, particularly rhinocerebral form.
  • Long-term:
    • Recurrent DKA: Leads to increased morbidity, hospitalizations, and impaired quality of life. Often indicates underlying issues with diabetes management or psychological factors.
    • Progression of Microvascular and Macrovascular Complications: Poor glycemic control and recurrent DKA contribute to long-term complications of diabetes (retinopathy, nephropathy, neuropathy, cardiovascular disease).

Prognosis

  • Factors Affecting Outcome:
    • Severity of DKA: Patients with severe DKA (pH <7.0) have a worse prognosis.
    • Age: Extremes of age (very young children, elderly) are at higher risk of complications and mortality.
    • Presence of Comorbidities: Underlying cardiac, renal, or pulmonary disease increases risk.
    • Precipitating Factor: Septic shock or severe MI as a trigger leads to worse outcomes.
    • Promptness and Appropriateness of Treatment: Early diagnosis and adherence to treatment protocols significantly improve prognosis.
    • Development of Complications: Cerebral edema and ARDS are associated with high mortality.
  • Survival:
    • Overall mortality in developed countries is low, typically <1%.
    • Mortality rates are higher in developing countries (up to 5-10%).
    • In children, mortality is primarily related to cerebral edema.
  • Quality of Life:
    • Patients experiencing DKA, especially recurrent episodes, may suffer from psychological distress, fear of recurrence, and significant impact on their daily lives.
    • Successful prevention of recurrence and robust diabetes self-management education are key to improving long-term quality of life.

Prevention

  • Primary Prevention (Preventing initial occurrence):
    • Diabetes Education: Comprehensive education for all diabetes patients on self-management, including sick day rules, insulin use, and ketone monitoring.
    • Consistent Insulin Use: Emphasize adherence to prescribed insulin regimen.
    • Early Recognition of Type 1 Diabetes: Promote awareness of T1DM symptoms (polyuria, polydipsia, weight loss, fatigue) to enable early diagnosis and prevent DKA as the initial presentation.
    • Annual Flu Vaccination: To reduce the risk of common infections that can precipitate DKA.
  • Secondary Prevention (Early detection and intervention):
    • Sick Day Management: Educate patients to:
      • Continue insulin, potentially increasing doses as instructed.
      • Monitor blood glucose every 2-4 hours.
      • Test for ketones (urine or blood β-hydroxybutyrate) if blood glucose >250-300 mg/dL or during illness.
      • Maintain adequate fluid and electrolyte intake (sugar-free liquids).
      • Contact healthcare provider if unable to eat/drink, persistent vomiting, high ketones, or worsening symptoms.
    • Prompt Medical Attention: Emphasize seeking immediate medical care if DKA symptoms develop.
    • Regular Follow-up: Ensure patients have access to and utilize regular medical appointments to optimize diabetes control.
  • Tertiary Prevention (Preventing complications and recurrence):
    • Optimization of Glycemic Control: Achieve individualized HbA1c targets to reduce overall risk.
    • Addressing Psychosocial Factors: Identify and address issues like depression, anxiety, eating disorders, or financial barriers that contribute to insulin non-adherence.
    • Insulin Pump Therapy: May be considered for patients with recurrent DKA despite optimal multiple daily injection (MDI) regimens, as it offers more flexible insulin delivery.
    • Continuous Glucose Monitoring (CGM): Can help detect glucose trends and impending hyperglycemia, allowing for proactive intervention.

Special Populations

  • Pediatric:
    • Higher Risk of Cerebral Edema: The most feared complication. Causes are multifactorial, but rapid fluid shifts and bicarbonate administration are implicated.
    • Fluid Management: Slower, more careful fluid resuscitation (10-20 mL/kg bolus, then replacement over 24-48 hours) to prevent rapid drops in osmolality. No routine bicarbonate.
    • Insulin Infusion: Usually 0.05-0.1 units/kg/hr, no bolus.
    • Monitoring: Extremely close neurological monitoring (hourly Glasgow Coma Scale, vital signs).
    • Initial Presentation: DKA is the initial presentation in 25-40% of newly diagnosed T1DM children.
  • Geriatric:
    • Higher Mortality: Due to comorbidities, decreased physiological reserve, and often delayed presentation.
    • Comorbidities: Increased risk of fluid overload (heart failure), electrolyte disturbances (renal insufficiency), and severe infections.
    • Fluid Management: Careful assessment of cardiac status is crucial to avoid fluid overload.
    • Mental Status: Altered mental status may be subtle or attributed to other causes.
    • Polypharmacy: Risk of drug interactions.
  • Pregnancy:
    • Increased Risk of DKA: Due to physiological changes (insulin resistance, increased counter-regulatory hormones) and often nausea/vomiting. Occurs more frequently in T1DM.
    • Fetal Implications: DKA is associated with high fetal mortality (up to 30%), preterm labor, and fetal distress.
    • Management: Insulin is the preferred treatment (insulin does not cross the placenta). Careful fluid management. Close monitoring of both mother and fetus (fetal heart rate monitoring). Euglycemic DKA can occur.
  • Comorbidities:
    • Heart Failure: Requires cautious fluid administration, close hemodynamic monitoring, and potentially lower fluid rates.
    • Renal Failure: Careful monitoring of potassium and phosphate; insulin dosing may need adjustment. Patients on dialysis may require unique management strategies.
    • SGLT2 Inhibitor Use: High index of suspicion for euglycemic DKA. Management is similar, but glucose levels may be normal. Hold SGLT2 inhibitor.
    • Severe Infection/Sepsis: Prompt initiation of broad-spectrum antibiotics once cultures are obtained. Vasopressors may be needed for shock.

Clinical Pearls

  • Diagnostic:
    • Don't rely solely on urine ketones: Urine dipsticks measure acetoacetate, which may be negative or only mildly positive even in severe DKA if β-hydroxybutyrate is the predominant ketone. Furthermore, urine ketones may remain positive even after DKA resolution as β-hydroxybutyrate converts to acetoacetate during recovery. Always prefer serum β-hydroxybutyrate for diagnosis and monitoring.
    • Anion Gap is key: A normal glucose does not rule out DKA (euglycemic DKA), but an elevated anion gap with ketonemia is diagnostic.
    • Always look for the precipitating cause: Treating DKA without addressing the underlying trigger leads to recurrence or persistent illness.
    • Corrected Sodium: Remember to correct serum sodium for hyperglycemia (for every 100 mg/dL increase in glucose above 100 mg/dL, add 1.6-2.0 mEq/L to measured sodium).
    • Pseudohyperkalemia: Hemolysis during blood draw can cause artifactually high potassium. Confirm with a repeat sample if clinically unexpected.
  • Treatment:
    • Fluids First, Then Insulin: Adequate rehydration is paramount for tissue perfusion and lowering glucose by improving renal excretion. Insulin should generally be started after initial fluid bolus.
    • Potassium Management is Crucial: Hypokalemia is a significant risk, and severe hypokalemia can cause fatal arrhythmias. Always replete potassium once levels are <5.0-5.2 mEq/L and continue throughout treatment, even if initially normal.
    • Avoid Rapid Glucose Correction: Aim for a gradual fall of glucose by 50-75 mg/dL/hr. Too rapid a fall, especially in children, increases the risk of cerebral edema.
    • Continue Insulin Infusion Until DKA Resolution: Do not stop the insulin infusion once glucose normalizes; switch to dextrose-containing fluids. The insulin infusion must continue until the anion gap closes, bicarbonate normalizes, and ketosis resolves.
    • Bridge IV to SQ Insulin: Administer the first dose of long-acting (basal) subcutaneous insulin 1-2 hours before discontinuing the IV insulin infusion to prevent rebound hyperglycemia and ketosis.
  • Pitfalls:
    • Under-resuscitation with fluids: Leads to persistent dehydration, impaired renal perfusion, and slower resolution of DKA.
    • Over-resuscitation with fluids: Can lead to fluid overload, especially in patients with cardiac or renal dysfunction.
    • Failure to replace potassium adequately: Can lead to life-threatening arrhythmias.
    • Premature discontinuation of IV insulin: Before resolution of acidosis and ketonemia.
    • Aggressive bicarbonate use: Except in extreme acidosis (pH <6.9), which can worsen outcomes.
    • Failure to diagnose/treat precipitating factor: Leading to treatment failure or recurrence.
    • Missing cerebral edema in children: Requires high index of suspicion and prompt treatment.

Recent Updates

  • SGLT2 Inhibitor Associated DKA: Growing recognition of euglycemic DKA (eu-DKA) in patients on SGLT2 inhibitors. Management is similar to typical DKA, but careful attention to the euglycemic state is needed, requiring dextrose-containing fluids earlier. The SGLT2 inhibitor should be temporarily or permanently discontinued during and after DKA.
  • Intravenous vs. Subcutaneous Insulin Regimens: While IV insulin infusion remains the gold standard for moderate to severe DKA, some studies explore the use of subcutaneous rapid-acting insulin analogs (e.g., lispro) in mild-moderate DKA in carefully selected patients in non-ICU settings, but this is not yet standard practice and requires careful patient selection and monitoring.
  • Role of Bicarbonate: Current guidelines continue to strongly recommend against routine bicarbonate administration, reserving it only for severe acidosis (pH <6.9 or severe cardiovascular instability).
  • Fluid Choice: Balanced crystalloid solutions (e.g., Plasma-Lyte, Lactated Ringer's) are being investigated as alternatives to normal saline, potentially reducing the risk of hyperchloremic metabolic acidosis. However, 0.9% NS remains the widely accepted first-line fluid.

Key References

  • Guidelines:
    • American Diabetes Association (ADA): Standards of Medical Care in Diabetes - Latest edition, Chapter 16: Diabetes Management in Hospital Settings. (Regularly updated, consult the most recent version online).
    • Endocrine Society Clinical Practice Guideline: Management of Diabetic Ketoacidosis in Adults. (2009, often referenced).
    • International Society for Pediatric and Adolescent Diabetes (ISPAD): Clinical Practice Consensus Guidelines 2022 - DKA and Hyperglycemic Hyperosmolar State.
  • Studies:
    • Kitabchi AE, et al. (2001). Hyperglycemic Crises in Patients With Diabetes Mellitus. Diabetes Care. 24(1): 154-16 crises. (Classic review, foundational for management).
    • Dhatariya KK, et al. (2020). The Management of Diabetic Ketoacidosis (DKA) in Adults – An Updated Position Statement. Diabet Med. (Recent consensus statement).
    • Multiple Randomized Controlled Trials on fluid management (e.g., comparing NS vs. balanced crystalloids, bolus vs. continuous insulin, effects of bicarbonate).
  • Reviews:
    • UpToDate: Comprehensive topic reviews on Diabetic Ketoacidosis in Adults and Children.
    • Harrison's Principles of Internal Medicine: Chapter on Diabetes Mellitus and Metabolic Syndrome.
    • Braunwald's Heart Disease: A Textbook of Cardiovascular Medicine: Relevant sections on cardiovascular complications in diabetes.

Dr. Vivek's AI | For Educational Purposes Only